Dynavax Technologies (NASDAQ:DVAX) had its price target increased by research analysts at Royal Bank of Canada to $26.00 in a research note issued to investors on Monday, The Fly reports. The firm currently has an “outperform” rating on the biopharmaceutical company’s stock. Royal Bank of Canada’s price target indicates a potential upside of 114.17% from the company’s previous close.

Several other research firms have also recently weighed in on DVAX. Cantor Fitzgerald increased their target price on shares of Dynavax Technologies to $32.00 and gave the company an “overweight” rating in a research note on Monday. BidaskClub upgraded shares of Dynavax Technologies from a “strong sell” rating to a “sell” rating in a research note on Thursday, October 11th. Zacks Investment Research upgraded shares of Dynavax Technologies from a “sell” rating to a “hold” rating in a research note on Thursday, August 9th. Finally, ValuEngine cut shares of Dynavax Technologies from a “hold” rating to a “sell” rating in a research note on Monday, July 30th. Two equities research analysts have rated the stock with a sell rating, one has given a hold rating and four have assigned a buy rating to the company’s stock. The stock presently has a consensus rating of “Hold” and an average target price of $28.25.

Shares of NASDAQ:DVAX traded up $1.25 during midday trading on Monday, hitting $12.14. The company’s stock had a trading volume of 249,149 shares, compared to its average volume of 968,524. The company has a market cap of $681.88 million, a P/E ratio of -7.01 and a beta of 0.30. Dynavax Technologies has a fifty-two week low of $10.35 and a fifty-two week high of $23.85. The company has a debt-to-equity ratio of 0.76, a quick ratio of 8.67 and a current ratio of 8.87.

Dynavax Technologies (NASDAQ:DVAX) last issued its quarterly earnings results on Monday, August 6th. The biopharmaceutical company reported ($0.63) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.62) by ($0.01). The business had revenue of $1.25 million during the quarter, compared to analyst estimates of $1.88 million. Dynavax Technologies had a negative net margin of 8,570.06% and a negative return on equity of 72.31%. The company’s revenue for the quarter was up 1094.3% compared to the same quarter last year. During the same period in the prior year, the business posted ($0.41) earnings per share. As a group, equities analysts predict that Dynavax Technologies will post -2.39 EPS for the current year.

Several hedge funds and other institutional investors have recently added to or reduced their stakes in DVAX. Wells Fargo & Company MN lifted its stake in shares of Dynavax Technologies by 9.2% in the first quarter. Wells Fargo & Company MN now owns 45,516 shares of the biopharmaceutical company’s stock valued at $903,000 after buying an additional 3,834 shares during the period. New York State Common Retirement Fund lifted its stake in Dynavax Technologies by 10.8% during the first quarter. New York State Common Retirement Fund now owns 65,700 shares of the biopharmaceutical company’s stock worth $1,304,000 after purchasing an additional 6,400 shares during the period. California Public Employees Retirement System lifted its stake in Dynavax Technologies by 169.0% during the first quarter. California Public Employees Retirement System now owns 83,633 shares of the biopharmaceutical company’s stock worth $1,660,000 after purchasing an additional 52,545 shares during the period. Commonwealth Equity Services LLC bought a new position in Dynavax Technologies during the first quarter worth about $212,000. Finally, UBS Group AG lifted its stake in Dynavax Technologies by 175.9% during the first quarter. UBS Group AG now owns 254,687 shares of the biopharmaceutical company’s stock worth $5,056,000 after purchasing an additional 162,360 shares during the period. Institutional investors and hedge funds own 82.08% of the company’s stock.

About Dynavax Technologies

Dynavax Technologies Corporation, a biopharmaceutical company, focuses on leveraging the power of the body's innate and adaptive immune responses through toll-like receptor (TLR) stimulation. The company's lead product candidates include HEPLISAV-B, a hepatitis B vaccine for prevention of infection caused by all known subtypes of the virus in adults age 18 years and older; SD-101, a cancer immunotherapy that is in Phase 2 clinical studies; and DV281, an investigational TLR9 agonist for the treatment of non-small cell lung cancer.

See Also: Moving Average – How it Helps Investors in Stock Selection

The Fly

Receive News & Ratings for Dynavax Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Dynavax Technologies and related companies with MarketBeat.com's FREE daily email newsletter.